Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report) traded down 14.6% during trading on Monday . The stock traded as low as $10.10 and last traded at $11.40. 8,162,763 shares changed hands during trading, an increase of 678% from the average session volume of 1,049,645 shares. The stock had previously closed at $13.35.
Wall Street Analyst Weigh In
Separately, HC Wainwright raised their price target on Virios Therapeutics from $0.20 to $5.00 and gave the stock a "neutral" rating in a report on Wednesday, October 9th.
View Our Latest Analysis on VIRI
Virios Therapeutics Stock Performance
The stock has a 50-day moving average price of $2.88 and a two-hundred day moving average price of $1.92. The stock has a market capitalization of $335.09 million, a P/E ratio of -64.44 and a beta of 1.58.
About Virios Therapeutics
(
Get Free Report)
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Recommended Stories
Before you consider Virios Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Virios Therapeutics wasn't on the list.
While Virios Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
